Exchange: NYSEMkt·Updated 03:12 PM EST
CVM logo

CVM Cel-Sci Corp

$1.45
$0.07
(5.07%)
Today
Reported EarningsAug 17
Mkt Cap$24.27M
Vol180,216.00

About CVM

CEL-SCI Corp. is a clinical-stage biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients and CEL-2000 and CEL-4000, which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.
40

Bearish Sentiment

How do you feel about CVM?

BooBoo1868
$CVM The year is 2030. The first dinosaur was cloned and brought back. Flying cars are now mass produced. First contact with aleins are made public. News of Cvm approval in Saudi Arabia is expected any day....
11
Freetimeod
$CVM 50 YEARS Geert and his father-in-law have milked this. That isn't an exaggeration...50 years between the two of them they have been paying themselves handsomely and never, NEVER MADE ONE DIME for their shareholders.
7
GTA_Terminal
$CVM dark pool spike: 11.2x normal off-exchange volume on Monday (Nov 16), 734,000 shares worth about $1.2M (bullish). That came on a 29.7% gain in the stock. Technicals: pushed back over the 100 EMA, now beneath the price around $1.8. Source: GTA Terminal from Global Traders Academy.
1
2
Petro16
$CVM what the corrupt fda needs to do is approve this much needed therapy peoples lives could be saved!
5
itsverified
$CVM grabbed a few more pre market. I do think we see a multi day pump. Plus a move above the 200MA ($2.27) would make things interesting. I was born a gambling man.
4
Buddy5151
$CVM This stock and the people running aren’t worth the time or money. I agree get out while you can . I got out a long time ago and dam glad I did before they diluted this stock with probably a promising drug just mis managed!!
3
SchmittHappen
$CVM In today’s new video, Gerd said “We hope to sell our drug in Saudi Arabia beginning next year." FIVE YEARS OF HOPE. HOW MUCH LONGER WILL SHAREHOLDERS HAVE TO WAIT? David is once again celebrating Geert Kersten’s latest statement: “We hope to sell our drug in Saudi Arabia beginning next year.” Another HOPE? Let’s review CEL-SCI’s history. JUNE 2021: HOPE to obtain FDA approval following the Phase 3 results. More than five years later, still no approved BLA. 2023 — FDA: HOPE to file a BLA and secure regulatory approval. Still waiting. 2023 — EUROPE: HOPE to obtain European regulatory approval. Still waiting. 2023 — UNITED KINGDOM: HOPE to obtain UK approval and bring Multikine to market. Still waiting. 2023 — CANADA: HOPE to secure Canadian approval, with commercialization discussed as early as 2024. It’s almost November 2026. Still waiting. 2025 — SAUDI ARABIA: HOPE to receive SFDA Breakthrough Medicine Designation, with an approximately 60-day response timeline discussed. Still waiting. 2025 — SAUDI COMMERCIALIZATION: HOPE for commercial availability by summer 2025. Summer came and went. 2025 — CONFIRMATORY TRIAL: HOPE to begin enrollment in spring 2026. Where is the clearly announced first patient enrolled? OCTOBER 2026 — SAUDI ARABIA: And now Geert HOPES to begin selling Multikine in Saudi Arabia in 2027. HOPE. HOPE. HOPE. HOPE. HOPE. Five years of optimistic regulatory statements, shifting commercialization expectations, and unfulfilled timelines. David interprets the latest HOPE as a major bullish signal. Why? What makes this particular statement more credible than all the previous ones? HOPE is not an FDA approval. HOPE is not an approved BLA. HOPE is not an SFDA designation. HOPE is not an enrolled confirmatory trial. HOPE is not revenue. At what point do shareholders stop celebrating what management HOPES to accomplish and start demanding evidence of what management has actually accomplished? CVM doesn’t need another HOPE. It needs RESULTS.
3
SchmittHappen
$CVM CEL-SCI’s Latest PR: More Promotional Spin, Same Failed Phase 3 Trial Let’s dissect today’s press release because the difference between what CEL-SCI is promoting and what it has actually demonstrated is enormous. 1. The 73.4% vs. 45% survival figures are NOT new. CEL-SCI continues recycling favorable survival statistics from a selected subgroup of its original Phase 3 trial. The company highlights a 66% reduction in the risk of death (HR 0.34) as though this represents a new clinical breakthrough. It doesn’t. These are analyses of existing patients from a trial that failed to meet its primary endpoint in the overall study population. No amount of repetition changes that fundamental fact. 2. The subgroup analysis is the elephant in the room. The headline survival figures involve just 114 patients selected from a much larger trial. Why does that matter? Because a favorable result in a selected subgroup does not carry the same evidentiary weight as a successful, prospectively defined primary endpoint. Subgroup analyses can generate hypotheses. They can identify potentially promising patient populations. But they can also exaggerate treatment effects, particularly when multiple analyses are conducted. The company emphasizes the most favorable numbers while investors are left to determine how much confidence those numbers actually deserve. 3. The 38% vs. 13% downstaging result is not proof of a survival benefit. Today’s release also highlights a statistically significant difference in presurgical downstaging, reporting p=0.003. Sounds impressive, right? But downstaging is not the same as demonstrating improved overall survival. It’s an intermediate clinical measure, and its significance depends on how it was defined, assessed, and analyzed. A statistically significant secondary or exploratory finding does not retroactively rescue a failed primary endpoint. 4. The 66% reduction in mortality risk is being presented without sufficient context. A hazard ratio of 0.34 sounds extraordinary. But where is the emphasis on the confidence intervals, the subgroup selection methodology, the number of events, and the statistical limitations associated with these analyses? Those details are essential to evaluating the reliability of the result. A hazard ratio derived from a selected subgroup cannot simply be treated as definitive proof that a drug reduces mortality by 66% across its intended treatment population. 5. The Rome presentation is not independent validation. CEL-SCI is using a conference presentation to generate another promotional headline. Presenting an analysis at a medical conference does not establish that the results have been independently replicated, accepted by regulators, or confirmed in another clinical trial. A conference podium is not an FDA approval. A presentation is not a successful confirmatory study. The venue doesn’t strengthen the underlying evidence. 6. What’s conspicuously absent from today’s announcement? No new randomized clinical trial results. No independent replication of the survival findings. No regulatory approval. No new definitive evidence resolving the original Phase 3 failure. No financing announcement or funded strategic partnership. Instead, shareholders receive another carefully constructed narrative built around favorable analyses of historical data. THE BOTTOM LINE CEL-SCI seems remarkably skilled at converting the same clinical dataset into an endless supply of optimistic press releases. The company wants investors focused on impressive percentages, dramatic hazard ratios, and prestigious-sounding presentations. But the fundamental scientific question remains unanswered: Can Multikine’s reported benefit in this selected population be reliably reproduced? Until that happens, these numbers remain promising but unconfirmed subgroup findings—not definitive evidence of efficacy. You cannot press-release your way to clinical success. You cannot market a failed primary endpoint into a positive one. And you cannot substitute promotional repetition for independent validation. At some point, investors need to stop counting press releases and start demanding genuinely new evidence.
3
Freetimeod
$CVM It's Friday the 13th, probably an excellent metaphor for this company...and probably the day they announce they are rolling down the shutters.
2
BioGLovesMe
$CVM Another great day at the junk bio casino. Dilution is now a matter of when, not if.
2
prophet777
$CVM Geert maybe you can explain to your investors mate why it’s taking you 500 days to BMD in Saudi Arabia where normally it takes 30 days. Maybe you can explain why Dallah Pharma didn’t want to play ball with you and instead you got Amarox. Maybe sfda told you to take a hike and now you are trying a different route. Also, what happened to your partners... It would be nice to get some answers from you… especially when you are getting paid a million a year and not delivering… maybe cut your salary buddy…
2
SchmittHappen
$CVM A simple question you keep avoiding: When exactly is CEL-SCI’s confirmatory Phase 3 trial going to start? We’ve heard years of promises, presentations, conferences, and optimistic projections, yet shareholders still don’t have a firm trial start date. What’s the holdup? Funding? Regulatory issues? Trial design? Or something else? Enough promotional rhetoric. Give investors an actual timeline.
2
drkazmd65
$CVM - Decent volume AND a 20+% share price increase - and I can't find anything news related for the company. Still way below the 52-week high - so absolutely nothing to get excited about though.
1
Johnyd
$CVM also, place was filled up with arabs. i doubt many of them are real doctors. why do they always avoid the FDA?
1
prophet777
$CVM hey Geert when is your fda study upcoming! 2036 or 2046 or who cares as long as you and your homies get paid… enlight us mate…
1
prophet777
$CVM Geert you have another dumb presentation in Rome coming up. How about: a clear SFDA status, actual fda trial enrollment, and enough financing to reach the next milestone... give us real update not the same kebab in a new package…
1
BioGLovesMe
$CVM I would be very careful if you're trying to flip pennies here. They need to dilute before the end of the year, and you dont want to be caught holding the bag. The actual fundamentals are also horrendous: their only clinical candidate failed its P3 all the way back in 2021, and zero progress has been made to advance it. Otherwise, welcome to CVM Bagholder's Anonymous. Respected elder will take your hat and jacket.
itsverified
$CVM I think there will be a multi day pump here. Buyer beware. This pump stinks. Would love for it to be ahead of some actual news but we all know the reality
BioGLovesMe
$CVM Ah yes the good old pump into dilution. Bulls should check their last 10Q: they had about a quarter's worth of cash left as of June 30th. Don't become another permabaggie.
SemiRetiredEngineer
$CVM Folks are doing the company's cash position analysis I'd think..... nothing surprising here other than that it's gone this far without a raise....

Advertisement|Remove ads.